Related Experiment Videos

Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity

David J Browning1

  • 1Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina 28210, USA. djbrowning@carolina.rr.com

Abstract

Insights

New cases of hydroxychloroquine and chloroquine retinopathy are still occurring, even with screening. Physicians must pay closer attention to dosing and early visual field defects to prevent this avoidable toxicity.

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Hydroxychloroquine and chloroquine are commonly prescribed for autoimmune conditions.
  • Retinopathy is a known potential side effect of these medications.

Observation:

  • A retrospective observational case series reviewed six patients with retinopathy.
  • Data included clinical records, visual fields, fundus photography, and fluorescein angiography.

Findings:

  • All six cases resulted from physicians exceeding recommended safe dosing levels.
  • Five cases developed despite adherence to established ophthalmologic screening protocols.
  • Patients exhibited parafoveal retinal pigment epithelial atrophy and paracentral visual field defects.

Implications:

  • Hydroxychloroquine and chloroquine toxicity remains a concern despite current screening practices.
  • Increased physician awareness of safe dosing and early visual field abnormalities is crucial.
  • Proactive ophthalmologic monitoring can help mitigate the incidence of this preventable condition.

Related Concept Videos